- 商品介绍
- 规格参数
- 包装参数
Biochem/physiol Actions
DT2216 is a selective BCL-XL, but not BCL-2 or BCL-W, degrader composed of a von Hippel-Lindau (VHL) E3 ligase-targeting ligand linked to a ABT-263 (navitoclax) derivative. DT2216 is more potent than ABT-263 against BCL-XL-dependent leukemia (MOLT-4 IC50 = 52 vs 191 nM) and cancer cells (MDA-MB-231 IC50 = 229 vs 707 nM). DT2216 effectively inhibits the growth of several xenograft tumors in vivo either alone (15 mg/kg/wk i.p.) or in combination with other chemotherapeutic agents (docetaxel or VDL), exhbiting improved efficacy and reduced thrombocytopenia when compared with ABT-263 as a result of greatly reduced platelet toxicity due to poor VHL expression in platelets.
Selective BCL-XL degrader composed of a von Hippel-Landau (VHL) E3 ligase-targeting ligand linked to a ABT-263 (navitoclax) derivative.
| Quality Level | 100 |
| assay | ≥90% (HPLC) |
| form | powder |
| color | white to beige |
| solubility | DMSO: 2 mg/mL, clear (Warmed) |
| storage temp. | -10 to -25°C |
| SMILES string | CC(C)(C1)CCC(C2=CC=C(C=C2)Cl)=C1CN3CCN(C4=CC=C(C=C4)C(NS(=O)(C5=CC(S(C(F)(F)F)(=O)=O)=C(C=C5)N[C@@H](CSC6=CC=CC=C6)CCN7CCN(CC7)C(CCCCCC(N[C@@H](C(C)(C)C)C(N8[C@@H](C[C@H](C8)O)C(N[C@H](C9=CC=C(C%10=C(N=CS%10)C)C=C9)C)=O)=O)=O)=O)=O)=O)CC3 |
| InChI | 1S/C77H96ClF3N10O10S4/c1-51(53-18-20-55(21-19-53)70-52(2)82-50-103-70)83-73(96)66-44-61(92)48-91(66)74(97)71(75(3,4)5)85-68(93)16-12-9-13-17-69(94)90-42-36-87(37-43-90)35-33-59(49-102-62-14-10-8-11-15-62)84-65-31-30-63(45-67(65)104(98,99)77(79,80)81)105(1 |
| InChI key | PXVFFBGSTYQHRO-REQIQPEASA-N |
| 长度(mm) | |
| 宽度(mm) | |
| 高度(mm) | |
| 重量(kg) |
-
¥ 2290.21
-
¥ 1573.49
-
¥ 9207.92
-
询价
-
询价
-
¥ 1956.41
-
询价
-
¥ 6330.00
-
¥ 3290.05
-
询价
-
询价
-
瓶顶过滤器-500ml容量,MF75TM系列，聚苯乙烯外壳，75mmPES滤膜，孔径0.45um,适合瓶颈尺寸33mm，12/箱，295-3345，Nalgene，Thermofisher，赛默飞世尔¥ 1938.54
-
询价
-
¥ 4404.38
-
¥ 1783.21
-
¥ 787.34
-
¥ 3476.87
-
¥ 3796.67
-
¥ 65710.50
-
询价
微信小程序
7X24小时在线咨询